miRagen Therapeutics

Cardiovascular disease is the leading cause of death globally. Astonishingly, every 37 seconds a person dies in the United States from cardiovascular disease. For survivors, life changes dramatically after an adverse heart event.

Because of the significant toll that cardiovascular and muscle disease takes on patients, in 2007 miRagen Therapeutics, Inc. was established to improve patients’ lives by developing innovative microRNA (miRNA) based therapeutics for cardiovascular and muscle disease.

At miRagen, we have a true passion for advancing science and miRNAs are the cutting edge of innovation. A recently discovered class of small RNAs encoded in the genome, miRNAs are short, single-stranded RNA molecules that regulate gene expression with the potential to play a vital role in influencing the pathways responsible for cardiovascular and muscle disease.

With founders who are world recognized as leaders in their fields and in-house bench scientists with unprecedented expertise in miRNA biology and chemistry, miRagen is tackling debilitating diseases by discovering and developing innovative miRNA therapies to improve human health.